Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829060 · ClinicalTrials.gov registry record · NA
Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 330
- Enrollment target
NCT02829060 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 330 participants.
The verdict
NCT02829060, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 330 participants
- Enrollment target
Study Summary
This study will be a multi-institutional randomized clinical trial of a short course of pre-operative antibiotic prophylaxis in addition to perioperative antibiotics prior to undergoing percutaneous nephrolithotomy. The select patient population will be those patients deemed to be at a moderately increased risk of postoperative infectious complications. These higher risk patients are those with indwelling urinary drainage tubes and those with a positive preoperative urine culture.
Interventions
- DRUG Nitrofurantoin 100 MG, 7d
- DRUG Gentamicin, 5mg/kg
- DRUG Ampicillin 2g
- DRUG Nitrofurantoin 100 mg, 48 hrs
- DRUG Gentamicin, 80 mg, 7d
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2016-01 |
| Est. Completion | 2025-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02829060
The ClinicalTrials.gov registry entry for NCT02829060 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nitrofurantoin 100 MG, 7d is the first listed.
NCT02829060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02829060 about?
NCT02829060 is a clinical study titled "Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2". This study will be a multi-institutional randomized clinical trial of a short course of pre-operative antibiotic prophylaxis in addition to perioperative antibiotics prior to undergoing percutaneous nephrolithotomy. The select patient population will be those patients deemed to be at a moderately in...
What is the current status of trial NCT02829060?
This trial is currently completed. It is a NA study. The enrollment target is 330 participants. The study started on 2016-01. Estimated completion is 2025-03.
What interventions are being tested in trial NCT02829060?
The interventions under investigation include: Nitrofurantoin 100 MG, 7d (DRUG), Gentamicin, 5mg/kg (DRUG), Ampicillin 2g (DRUG), Nitrofurantoin 100 mg, 48 hrs (DRUG), Gentamicin, 80 mg, 7d (DRUG).
Who is sponsoring clinical trial NCT02829060?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.